PRKCI-ECT2 copy number gain promotes developmental reprogramming and metastatic competence in lung adenocarcinoma
Cell Reports · 2026-07 · 45 (7) · 117697
DOI: 10.1016/j.celrep.2026.117697 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2026-07. Verfasst von Duy T Nguyen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA; Department of Molecular Pharmacology and Experimental Therapeut…. Hauptthemen laut MEDLINE: Protein Kinase C, Lung Neoplasms, Adenocarcinoma of Lung, Proto-Oncogene Proteins. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute.
Abstract (Originalsprache)
Lung adenocarcinoma (LUAD) shows extensive lineage plasticity and early metastatic dissemination, but the oncogenic events that actively drive these processes remain poorly defined. Here, we identify coordinated PRKCI and ECT2 copy number gain, present in approximately 30% of human LUADs, as a driver of developmental reprogramming and metastasis. Using a genetically engineered mouse model that recapitulates PRKCI-ECT2 gain in Kras/Trp53-driven LUAD, we show that elevated PKCι-ECT2 signaling rewires tumor trajectory in a cell-of-origin-dependent manner. Alveolar type II cell-derived tumors dedifferentiate into a distal SOX9high progenitor-like state associated with aggressive growth and liver metastasis, whereas club cell-derived tumors transition into a foregut SOX2high progenitor-like state that supports lineage infidelity and histological transformation. Human LUAD analyses support these progenitor programs as clinically relevant features of PRKCI-ECT2 gain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.
- Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA; Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA.
- Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.
- Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Pediatrics, Mayo Clinic College of Medicine, Rochester, MN, USA.
- Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA.
- Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN, USA; Department of Pediatrics, Mayo Clinic College of Medicine, Rochester, MN, USA; Paul F. Glenn Center for Biology of A…
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
Zitieren
APA
Nguyen, D. T., Meneses, K. M., Zhang, C., Prieto, L. I., Weems, C., Jamieson, L., Li, H., Baker, D. J., Khoor, A., Murray, N. R., Justilien, V., & Fields, A. P. (2026). PRKCI-ECT2 copy number gain promotes developmental reprogramming and metastatic competence in lung adenocarcinoma. Cell Reports, 45(7), 117697. https://doi.org/10.1016/j.celrep.2026.117697
Vancouver
Nguyen DT, Meneses KM, Zhang C, Prieto LI, Weems C, Jamieson L, et al. PRKCI-ECT2 copy number gain promotes developmental reprogramming and metastatic competence in lung adenocarcinoma. Cell Reports. 2026;45(7):117697. doi:10.1016/j.celrep.2026.117697
BibTeX
@article{Nguyen2026,
author = {Nguyen, Duy T and Meneses, Kayleah M and Zhang, Cheng and Prieto, Luis I and Weems, Capella and Jamieson, Lee and Li, Hu and Baker, Darren J and Khoor, Andras and Murray, Nicole R and Justilien, Verline and Fields, Alan P},
title = {PRKCI-ECT2 copy number gain promotes developmental reprogramming and metastatic competence in lung adenocarcinoma},
journal = {Cell Reports},
year = {2026},
volume = {45},
number = {7},
pages = {117697},
doi = {10.1016/j.celrep.2026.117697}
}
EUVIMED